v3.26.3
Discontinued Operations - Schedule of Balance Sheets and the Results of Operations of the Company Classified as Discontinued Operations (Details) - USD ($)
 3 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Jun. 30, 2026
Dec. 31, 2025
Net assets disposal of:        
Due to the Company     $ (8,602,603) $ (6,432,919)
Gain on disposal of subsidiaries:        
Total net liabilities disposed of $ 12,622,648      
Release of the translation of subsidiaries in foreign currency charged to other comprehensive loss in prior periods 879,769      
Cash consideration 513,000      
Gain on disposal of subsidiaries 14,015,417      
Net cash inflow (outflow) arising from disposal        
Cash consideration received during the year 23,000      
Cash disposed of (2,604,850)      
Net cash inflow (outflow) arising from disposal (2,581,850)      
Operating expenses:        
Research and development expenses $ 235,992    
General and administrative expenses 140,767    
Total operating expenses 376,759    
Operating loss (376,759)    
Other income:        
Interest income 448    
Other income, net 136,565    
Total other income, net 137,013    
Loss before tax expense (239,746)    
Income tax expense    
Loss from discontinued operations, net of tax $ (239,746)    
Hong Kong Subsidiary [Member]        
Net assets disposal of:        
Cash       5,926
Due from Advanced Biomed Inc. (Taiwan)       438,720
Prepaid expenses and other current assets, net       889,055
Equipment, net       155,270
Right-of-use assets      
Other non-current assets, net       214,497
Accounts payable, accruals, and other current liabilities       (299,904)
Lease liabilities (current and non-current)      
Due to the Company     (661,516)
Due to related parties     (163,706)
Tax payable       (180)
Total net liabilities disposed of       (5,193,241)
Gain on disposal of subsidiaries:        
Total net liabilities disposed of 5,193,241      
Release of the translation of subsidiaries in foreign currency charged to other comprehensive loss in prior periods 450,526      
Cash consideration 23,000      
Gain on disposal of subsidiaries 5,666,767      
Net cash inflow (outflow) arising from disposal        
Cash consideration received during the year 23,000      
Cash disposed of (5,926)      
Net cash inflow (outflow) arising from disposal 17,074      
Taiwan Subsidiary [Member]        
Net assets disposal of:        
Cash     2,598,924  
Due from Advanced Biomed Inc. (Taiwan)      
Prepaid expenses and other current assets, net     49,989  
Equipment, net     97,023  
Right-of-use assets     32,432  
Other non-current assets, net      
Accounts payable, accruals, and other current liabilities     (397,101)  
Lease liabilities (current and non-current)     (32,432)  
Due to related parties     (514,123)
Tax payable      
Total net liabilities disposed of     $ (7,429,407)  
Gain on disposal of subsidiaries:        
Total net liabilities disposed of 7,429,407      
Release of the translation of subsidiaries in foreign currency charged to other comprehensive loss in prior periods 429,243      
Cash consideration 490,000      
Gain on disposal of subsidiaries 8,348,650      
Net cash inflow (outflow) arising from disposal        
Cash consideration received during the year      
Cash disposed of (2,598,924)      
Net cash inflow (outflow) arising from disposal $ (2,598,924)